Good News for Exelixis and for Japanese Renal Cell Carcinoma Patients

Exelixis, Takeda and Japanese RCC Patients
Today we learned from Exelixis (EXEL) that Takeda Pharmaceutical Company Limited, which is responsible for the clinical development and commercialization of Exelixis' oncology drug  CABOMETYX® (cabozantinib . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.